000123967 001__ 123967
000123967 005__ 20240319081028.0
000123967 0247_ $$2doi$$a10.3390/pharmaceutics14122763
000123967 0248_ $$2sideral$$a132441
000123967 037__ $$aART-2022-132441
000123967 041__ $$aeng
000123967 100__ $$0(orcid)0000-0002-1407-5922$$aArauzo, Beatriz$$uUniversidad de Zaragoza
000123967 245__ $$aEngineering alginate-based dry powder microparticles to a size suitable for the direct pulmonary delivery of antibiotics
000123967 260__ $$c2022
000123967 5060_ $$aAccess copy available to the general public$$fUnrestricted
000123967 5203_ $$aThe inhaled route is regarded as one of the most promising strategies as a treatment against pulmonary infections. However, the delivery of drugs in a dry powder form remains challenging. In this work, we have used alginate to form microparticles containing an antibiotic model (colistin sulfate). The alginate microparticles were generated by atomization technique, and they were characterized by antimicrobial in vitro studies against Pseudomonas aeruginosa. Optimization of different parameters allowed us to obtain microparticles as a dry powder with a mean size (Feret diameter) of 4.45 ± 1.40 µm and drug loading of 8.5 ± 1.50%. The process developed was able to concentrate most of the colistin deposits on the surface of the microparticles, which could be observed by SEM and a Dual-Beam microscope. This produces a fast in vitro release of the drug, with a 100% release achieved in 4 h. Physicochemical characterization using the FTIR, EDX and PXRD techniques revealed information about the change that occurs from the amorphous to a crystalline form of colistin. Finally, the cytotoxicity of microparticles was tested using lung cell lines (A549 and Calu-3). Results of the study showed that alginate microparticles were able to inhibit bacterial growth while displaying non-toxicity toward lung cells.
000123967 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/PID2019-108994RB-I00
000123967 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000123967 590__ $$a5.4$$b2022
000123967 592__ $$a0.795$$b2022
000123967 591__ $$aPHARMACOLOGY & PHARMACY$$b50 / 278 = 0.18$$c2022$$dQ1$$eT1
000123967 593__ $$aPharmaceutical Science$$c2022$$dQ1
000123967 594__ $$a6.9$$b2022
000123967 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000123967 700__ $$aGonzález-Garcinuño, Álvaro
000123967 700__ $$aTabernero, Antonio
000123967 700__ $$0(orcid)0000-0002-1603-7305$$aCalzada-Funes, Javier$$uUniversidad de Zaragoza
000123967 700__ $$0(orcid)0000-0002-2436-1041$$aLobera, María Pilar$$uUniversidad de Zaragoza
000123967 700__ $$adel Valle, Eva M. Martín
000123967 700__ $$0(orcid)0000-0002-8701-9745$$aSantamaria, Jesús$$uUniversidad de Zaragoza
000123967 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000123967 773__ $$g14, 12 (2022), 2763 [19 pp.]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000123967 8564_ $$s4833229$$uhttps://zaguan.unizar.es/record/123967/files/texto_completo.pdf$$yVersión publicada
000123967 8564_ $$s2772696$$uhttps://zaguan.unizar.es/record/123967/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000123967 909CO $$ooai:zaguan.unizar.es:123967$$particulos$$pdriver
000123967 951__ $$a2024-03-18-16:56:16
000123967 980__ $$aARTICLE